Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O 2 Pathway Analysis

Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with a pressing shortage of therapies. Exercise intolerance is a cardinal symptom of HFpEF, yet its pathophysiology remains uncertain. We investigated the mechanism of exercise intolerance in 134 patients referred for cardio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2018-01, Vol.137 (2), p.148-161
Hauptverfasser: Houstis, Nicholas E, Eisman, Aaron S, Pappagianopoulos, Paul P, Wooster, Luke, Bailey, Cole S, Wagner, Peter D, Lewis, Gregory D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 161
container_issue 2
container_start_page 148
container_title Circulation (New York, N.Y.)
container_volume 137
creator Houstis, Nicholas E
Eisman, Aaron S
Pappagianopoulos, Paul P
Wooster, Luke
Bailey, Cole S
Wagner, Peter D
Lewis, Gregory D
description Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with a pressing shortage of therapies. Exercise intolerance is a cardinal symptom of HFpEF, yet its pathophysiology remains uncertain. We investigated the mechanism of exercise intolerance in 134 patients referred for cardiopulmonary exercise testing: 79 with HFpEF and 55 controls. We performed cardiopulmonary exercise testing with invasive monitoring to measure hemodynamics, blood gases, and gas exchange during exercise. We used these measurements to quantify 6 steps of oxygen transport and utilization (the O pathway) in each patient with HFpEF, identifying the defective steps that impair each one's exercise capacity (peak Vo ). We then quantified the functional significance of each O pathway defect by calculating the improvement in exercise capacity a patient could expect from correcting the defect. Peak Vo was reduced by 34±2% (mean±SEM,
doi_str_mv 10.1161/CIRCULATIONAHA.117.029058
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1161_CIRCULATIONAHA_117_029058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28993402</sourcerecordid><originalsourceid>FETCH-LOGICAL-c143t-a59dd22cbdb66391e2e7dd3f274dc2300fcaa3cf9cff65f0c4e0b31ff196b2b13</originalsourceid><addsrcrecordid>eNpVkE1OwzAUhC0EglK4AjIHSPFPfmp2UWhppIpWiIpl5NjP4FIcZKdAuQU3JrSAxOrNm9HM4kPonJIBpSm9KMrbYjHN78rZTT7JOy8bECZIMtxDPZqwOIoTLvZRjxAioowzdoSOQ1h2b8qz5BAdsaEQPCashz5H7-CVDYBL1zYr8NIpwNbhCUjf4rG0q7UHfG_bRzz3EMC_gsajJajWNg6PvdyKS3xl5YNrgnUPWDqNb6V7-tZlG3Ah1wECXmzDOfjQOLmyH93ODDM8l-3jm9zgvDM3wYYTdGDkKsDpz-2jxXh0V0yi6ey6LPJppGjM20gmQmvGVK3rNOWCAoNMa25YFmvFOCFGScmVEcqYNDFExUBqTo2hIq1ZTXkfid2u8k0IHkz14u2z9JuKkuobc_Ufc-dl1Q5z1z3bdV_W9TPov-YvV_4FMhR9yQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O 2 Pathway Analysis</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Houstis, Nicholas E ; Eisman, Aaron S ; Pappagianopoulos, Paul P ; Wooster, Luke ; Bailey, Cole S ; Wagner, Peter D ; Lewis, Gregory D</creator><creatorcontrib>Houstis, Nicholas E ; Eisman, Aaron S ; Pappagianopoulos, Paul P ; Wooster, Luke ; Bailey, Cole S ; Wagner, Peter D ; Lewis, Gregory D</creatorcontrib><description>Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with a pressing shortage of therapies. Exercise intolerance is a cardinal symptom of HFpEF, yet its pathophysiology remains uncertain. We investigated the mechanism of exercise intolerance in 134 patients referred for cardiopulmonary exercise testing: 79 with HFpEF and 55 controls. We performed cardiopulmonary exercise testing with invasive monitoring to measure hemodynamics, blood gases, and gas exchange during exercise. We used these measurements to quantify 6 steps of oxygen transport and utilization (the O pathway) in each patient with HFpEF, identifying the defective steps that impair each one's exercise capacity (peak Vo ). We then quantified the functional significance of each O pathway defect by calculating the improvement in exercise capacity a patient could expect from correcting the defect. Peak Vo was reduced by 34±2% (mean±SEM, &lt;0.001) in HFpEF compared with controls of similar age, sex, and body mass index. The vast majority (97%) of patients with HFpEF harbored defects at multiple steps of the O pathway, the identity and magnitude of which varied widely. Two of these steps, cardiac output and skeletal muscle O diffusion, were impaired relative to controls by an average of 27±3% and 36±2%, respectively ( &lt;0.001 for both). Due to interactions between a given patient's defects, the predicted benefit of correcting any single one was often minor; on average, correcting a patient's cardiac output led to a 7±0.5% predicted improvement in exercise intolerance, whereas correcting a patient's muscle diffusion capacity led to a 27±1% improvement. At the individual level, the impact of any given O pathway defect on a patient's exercise capacity was strongly influenced by comorbid defects. Systematic analysis of the O pathway in HFpEF showed that exercise capacity was undermined by multiple defects, including reductions in cardiac output and skeletal muscle diffusion capacity. An important source of disease heterogeneity stemmed from variation in each patient's personal profile of defects. Personalized O pathway analysis could identify patients most likely to benefit from treating a specific defect; however, the system properties of O transport favor treating multiple defects at once, as with exercise training.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIRCULATIONAHA.117.029058</identifier><identifier>PMID: 28993402</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Comorbidity ; Exercise Test ; Exercise Tolerance ; Female ; Health Status ; Heart Failure - diagnosis ; Heart Failure - metabolism ; Heart Failure - physiopathology ; Heart Failure - therapy ; Humans ; Male ; Middle Aged ; Muscle, Skeletal - metabolism ; Muscle, Skeletal - physiopathology ; Oxygen Consumption ; Predictive Value of Tests ; Prognosis ; Retrospective Studies ; Risk Factors ; Stroke Volume ; Ventricular Function, Left</subject><ispartof>Circulation (New York, N.Y.), 2018-01, Vol.137 (2), p.148-161</ispartof><rights>2017 American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c143t-a59dd22cbdb66391e2e7dd3f274dc2300fcaa3cf9cff65f0c4e0b31ff196b2b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,3688,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28993402$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Houstis, Nicholas E</creatorcontrib><creatorcontrib>Eisman, Aaron S</creatorcontrib><creatorcontrib>Pappagianopoulos, Paul P</creatorcontrib><creatorcontrib>Wooster, Luke</creatorcontrib><creatorcontrib>Bailey, Cole S</creatorcontrib><creatorcontrib>Wagner, Peter D</creatorcontrib><creatorcontrib>Lewis, Gregory D</creatorcontrib><title>Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O 2 Pathway Analysis</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with a pressing shortage of therapies. Exercise intolerance is a cardinal symptom of HFpEF, yet its pathophysiology remains uncertain. We investigated the mechanism of exercise intolerance in 134 patients referred for cardiopulmonary exercise testing: 79 with HFpEF and 55 controls. We performed cardiopulmonary exercise testing with invasive monitoring to measure hemodynamics, blood gases, and gas exchange during exercise. We used these measurements to quantify 6 steps of oxygen transport and utilization (the O pathway) in each patient with HFpEF, identifying the defective steps that impair each one's exercise capacity (peak Vo ). We then quantified the functional significance of each O pathway defect by calculating the improvement in exercise capacity a patient could expect from correcting the defect. Peak Vo was reduced by 34±2% (mean±SEM, &lt;0.001) in HFpEF compared with controls of similar age, sex, and body mass index. The vast majority (97%) of patients with HFpEF harbored defects at multiple steps of the O pathway, the identity and magnitude of which varied widely. Two of these steps, cardiac output and skeletal muscle O diffusion, were impaired relative to controls by an average of 27±3% and 36±2%, respectively ( &lt;0.001 for both). Due to interactions between a given patient's defects, the predicted benefit of correcting any single one was often minor; on average, correcting a patient's cardiac output led to a 7±0.5% predicted improvement in exercise intolerance, whereas correcting a patient's muscle diffusion capacity led to a 27±1% improvement. At the individual level, the impact of any given O pathway defect on a patient's exercise capacity was strongly influenced by comorbid defects. Systematic analysis of the O pathway in HFpEF showed that exercise capacity was undermined by multiple defects, including reductions in cardiac output and skeletal muscle diffusion capacity. An important source of disease heterogeneity stemmed from variation in each patient's personal profile of defects. Personalized O pathway analysis could identify patients most likely to benefit from treating a specific defect; however, the system properties of O transport favor treating multiple defects at once, as with exercise training.</description><subject>Aged</subject><subject>Comorbidity</subject><subject>Exercise Test</subject><subject>Exercise Tolerance</subject><subject>Female</subject><subject>Health Status</subject><subject>Heart Failure - diagnosis</subject><subject>Heart Failure - metabolism</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Muscle, Skeletal - metabolism</subject><subject>Muscle, Skeletal - physiopathology</subject><subject>Oxygen Consumption</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Stroke Volume</subject><subject>Ventricular Function, Left</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE1OwzAUhC0EglK4AjIHSPFPfmp2UWhppIpWiIpl5NjP4FIcZKdAuQU3JrSAxOrNm9HM4kPonJIBpSm9KMrbYjHN78rZTT7JOy8bECZIMtxDPZqwOIoTLvZRjxAioowzdoSOQ1h2b8qz5BAdsaEQPCashz5H7-CVDYBL1zYr8NIpwNbhCUjf4rG0q7UHfG_bRzz3EMC_gsajJajWNg6PvdyKS3xl5YNrgnUPWDqNb6V7-tZlG3Ah1wECXmzDOfjQOLmyH93ODDM8l-3jm9zgvDM3wYYTdGDkKsDpz-2jxXh0V0yi6ey6LPJppGjM20gmQmvGVK3rNOWCAoNMa25YFmvFOCFGScmVEcqYNDFExUBqTo2hIq1ZTXkfid2u8k0IHkz14u2z9JuKkuobc_Ufc-dl1Q5z1z3bdV_W9TPov-YvV_4FMhR9yQ</recordid><startdate>20180109</startdate><enddate>20180109</enddate><creator>Houstis, Nicholas E</creator><creator>Eisman, Aaron S</creator><creator>Pappagianopoulos, Paul P</creator><creator>Wooster, Luke</creator><creator>Bailey, Cole S</creator><creator>Wagner, Peter D</creator><creator>Lewis, Gregory D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20180109</creationdate><title>Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O 2 Pathway Analysis</title><author>Houstis, Nicholas E ; Eisman, Aaron S ; Pappagianopoulos, Paul P ; Wooster, Luke ; Bailey, Cole S ; Wagner, Peter D ; Lewis, Gregory D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c143t-a59dd22cbdb66391e2e7dd3f274dc2300fcaa3cf9cff65f0c4e0b31ff196b2b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Comorbidity</topic><topic>Exercise Test</topic><topic>Exercise Tolerance</topic><topic>Female</topic><topic>Health Status</topic><topic>Heart Failure - diagnosis</topic><topic>Heart Failure - metabolism</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Muscle, Skeletal - metabolism</topic><topic>Muscle, Skeletal - physiopathology</topic><topic>Oxygen Consumption</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Stroke Volume</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Houstis, Nicholas E</creatorcontrib><creatorcontrib>Eisman, Aaron S</creatorcontrib><creatorcontrib>Pappagianopoulos, Paul P</creatorcontrib><creatorcontrib>Wooster, Luke</creatorcontrib><creatorcontrib>Bailey, Cole S</creatorcontrib><creatorcontrib>Wagner, Peter D</creatorcontrib><creatorcontrib>Lewis, Gregory D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Houstis, Nicholas E</au><au>Eisman, Aaron S</au><au>Pappagianopoulos, Paul P</au><au>Wooster, Luke</au><au>Bailey, Cole S</au><au>Wagner, Peter D</au><au>Lewis, Gregory D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O 2 Pathway Analysis</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2018-01-09</date><risdate>2018</risdate><volume>137</volume><issue>2</issue><spage>148</spage><epage>161</epage><pages>148-161</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with a pressing shortage of therapies. Exercise intolerance is a cardinal symptom of HFpEF, yet its pathophysiology remains uncertain. We investigated the mechanism of exercise intolerance in 134 patients referred for cardiopulmonary exercise testing: 79 with HFpEF and 55 controls. We performed cardiopulmonary exercise testing with invasive monitoring to measure hemodynamics, blood gases, and gas exchange during exercise. We used these measurements to quantify 6 steps of oxygen transport and utilization (the O pathway) in each patient with HFpEF, identifying the defective steps that impair each one's exercise capacity (peak Vo ). We then quantified the functional significance of each O pathway defect by calculating the improvement in exercise capacity a patient could expect from correcting the defect. Peak Vo was reduced by 34±2% (mean±SEM, &lt;0.001) in HFpEF compared with controls of similar age, sex, and body mass index. The vast majority (97%) of patients with HFpEF harbored defects at multiple steps of the O pathway, the identity and magnitude of which varied widely. Two of these steps, cardiac output and skeletal muscle O diffusion, were impaired relative to controls by an average of 27±3% and 36±2%, respectively ( &lt;0.001 for both). Due to interactions between a given patient's defects, the predicted benefit of correcting any single one was often minor; on average, correcting a patient's cardiac output led to a 7±0.5% predicted improvement in exercise intolerance, whereas correcting a patient's muscle diffusion capacity led to a 27±1% improvement. At the individual level, the impact of any given O pathway defect on a patient's exercise capacity was strongly influenced by comorbid defects. Systematic analysis of the O pathway in HFpEF showed that exercise capacity was undermined by multiple defects, including reductions in cardiac output and skeletal muscle diffusion capacity. An important source of disease heterogeneity stemmed from variation in each patient's personal profile of defects. Personalized O pathway analysis could identify patients most likely to benefit from treating a specific defect; however, the system properties of O transport favor treating multiple defects at once, as with exercise training.</abstract><cop>United States</cop><pmid>28993402</pmid><doi>10.1161/CIRCULATIONAHA.117.029058</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2018-01, Vol.137 (2), p.148-161
issn 0009-7322
1524-4539
language eng
recordid cdi_crossref_primary_10_1161_CIRCULATIONAHA_117_029058
source MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals
subjects Aged
Comorbidity
Exercise Test
Exercise Tolerance
Female
Health Status
Heart Failure - diagnosis
Heart Failure - metabolism
Heart Failure - physiopathology
Heart Failure - therapy
Humans
Male
Middle Aged
Muscle, Skeletal - metabolism
Muscle, Skeletal - physiopathology
Oxygen Consumption
Predictive Value of Tests
Prognosis
Retrospective Studies
Risk Factors
Stroke Volume
Ventricular Function, Left
title Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Diagnosing and Ranking Its Causes Using Personalized O 2 Pathway Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T09%3A04%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exercise%20Intolerance%20in%20Heart%20Failure%20With%20Preserved%20Ejection%20Fraction:%20Diagnosing%20and%20Ranking%20Its%20Causes%20Using%20Personalized%20O%202%20Pathway%20Analysis&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Houstis,%20Nicholas%20E&rft.date=2018-01-09&rft.volume=137&rft.issue=2&rft.spage=148&rft.epage=161&rft.pages=148-161&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/CIRCULATIONAHA.117.029058&rft_dat=%3Cpubmed_cross%3E28993402%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28993402&rfr_iscdi=true